Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 1910-1920
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Solange Peters, Arnaud Scherpereel, Robin Cornelissen, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 488-499
Open Access | Times Cited: 185
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Persistent mutation burden drives sustained anti-tumor immune responses
Noushin Niknafs, Archana Balan, Christopher Cherry, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 440-449
Open Access | Times Cited: 87
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Lavanya Sivapalan, Joseph C. Murray, Jenna VanLiere Canzoniero, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005924-e005924
Open Access | Times Cited: 66
Tumour mutational burden: clinical utility, challenges and emerging improvements
Jan Budczies, Daniel Kazdal, Michael Menzel, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 725-742
Closed Access | Times Cited: 18
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Hedy L. Kindler, Nofisat Ismaila, Lyudmila Bazhenova, et al.
Journal of Clinical Oncology (2025) Vol. 43, Iss. 8, pp. 1006-1038
Closed Access | Times Cited: 3
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations
Michele Carbone, Harvey I. Pass, Güntülü Ak, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 7, pp. 873-889
Open Access | Times Cited: 67
Immunotherapy approaches for malignant pleural mesothelioma
Dean A. Fennell, Sean Dulloo, James Harber
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 9, pp. 573-584
Closed Access | Times Cited: 42
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 2, pp. 288-307
Open Access | Times Cited: 39
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Open Access | Times Cited: 39
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma
Peter W. Szlosarek, Ben Creelan, Thomas Sarkodie, et al.
JAMA Oncology (2024) Vol. 10, Iss. 4, pp. 475-475
Open Access | Times Cited: 13
Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort
Benjamin D. Leibowitz, Bonnie V. Dougherty, Joshua S. K. Bell, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 35
Immunotherapies in rare cancers
Sneha Vivekanandhan, Deborah Bahr, Ashish Kothari, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Maria Carmela Piccirillo, Quincy Chu, Penelope A. Bradbury, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 813-819
Closed Access | Times Cited: 17
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Ramaswamy Govindan, Charu Aggarwal, Scott Antonia, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e003956-e003956
Open Access | Times Cited: 26
Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape
Ibiayi Dagogo‐Jack, Russell W. Madison, Jochen K. Lennerz, et al.
JCO Precision Oncology (2022), Iss. 6
Closed Access | Times Cited: 25
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial
Peey‐Sei Kok, Patrick M. Forde, Brett Hughes, et al.
BMJ Open (2022) Vol. 12, Iss. 1, pp. e057663-e057663
Open Access | Times Cited: 24
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma
Marco Tagliamento, Paolo Bironzo, H. Curcio, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 172, pp. 103639-103639
Open Access | Times Cited: 23
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
Matteo Perrino, Fabio De Vincenzo, Nadia Cordua, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
Alena Laschtowitz, Christoph Roderburg, Frank Tacke, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 181-191
Open Access | Times Cited: 13
Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions
Yin P. Hung, Lucian R. Chirieac
Archives of Pathology & Laboratory Medicine (2024) Vol. 148, Iss. 5, pp. e77-e89
Open Access | Times Cited: 5
High density and proximity of CD8+T cells to tumor cells are correlated with better response to nivolumab treatment in metastatic pleural mesothelioma
Yuting Yin, Rie Sakakibara, Takayuki Honda, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 20, pp. 1991-2000
Open Access | Times Cited: 11
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
Aaron S. Mansfield, Jun Vivien Yin, Penelope A. Bradbury, et al.
Lung Cancer (2024) Vol. 195, pp. 107928-107928
Closed Access | Times Cited: 4
Current drug therapy for pleural mesothelioma
Hisao Imai
Respiratory Investigation (2025) Vol. 63, Iss. 2, pp. 200-209
Open Access
An overview of BAP1 biological functions and current therapeutics
Abdelrahman M. Elsayed, Muaiad Kittaneh, Colleen M. Cebulla, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189267-189267
Open Access
Page 1 - Next Page

Scroll to top